ABBV vs ABT
AbbVie Inc. vs Abbott Laboratories · Updated Aug 10, 2026
ABBV — 11 winsABT — 12 wins
Price Performance
ABBV +24.83%ABT -17.31%
Performance
| ABBV | ABT | |
|---|---|---|
| 1 Month | -0.40% | +15.36% |
| 3 Months | +22.59% | +28.51% |
| 6 Months | +10.59% | -0.66% |
| YTD | +8.14% | -13.51% |
| 1 Year | +24.25% | -17.24% |
| 3 Year | +65.78% | -0.24% |
| 5 Year | +114.02% | -10.43% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABBV | +8.1% | +27.3% | +11.2% | -4.6% | +19.3% | +28.4% | +19.6% | -0.8% | -6.3% | +55.0% | +8.7% | -10.1% |
| ABT | -12.5% | +10.4% | +3.0% | +0.5% | -21.0% | +29.0% | +25.9% | +25.0% | +23.0% | +46.1% | -10.5% | +0.0% |
Valuation
| ABBV | ABT | |
|---|---|---|
| P/E Ratio | 121.16 | 30.18 |
| Forward P/E | 17.51 | 19.55 |
| PEG Ratio | 4.00 | 3.49 |
| P/S Ratio | 6.92 | 4.13 |
| P/B Ratio | 15.81 | 2.82 |
| EV/EBITDA | 29.44 | 20.40 |
Financials
| ABBV | ABT | |
|---|---|---|
| EPS (TTM) | $2.04 | $3.59 |
| Gross Margin | +83.54% | +56.28% |
| Operating Margin | +31.56% | +16.50% |
| Net Margin | +4.66% | +9.65% |
| ROE | +13.23% | +9.50% |
| ROA | +2.67% | +5.07% |
| Debt/Equity | 2.65 | 0.52 |
Growth
| ABBV | ABT | |
|---|---|---|
| Revenue Growth YoY | +12.43% | +7.78% |
| Revenue Growth QoQ | -9.72% | -2.57% |
| EPS Growth YoY | -45.83% | -18.24% |
| EPS Growth QoQ | -61.76% | -39.22% |
Technical
| ABBV | ABT | |
|---|---|---|
| RSI (14) | 44.78 | 68.27 |
| % From 20-Day SMA | -1.98% | +5.35% |
| % From 50-Day SMA | +2.21% | +13.21% |
| % From 200-Day SMA | +9.73% | +0.55% |
| % From 52-Week High | -7.62% | -20.84% |
| % From 52-Week Low | +29.54% | +32.19% |
Analyst Ratings
ABBV
Buy(25 analysts)
Strong SellHoldStrong Buy
Price Target
$283.92
+15.62% upside
ABT
Buy(27 analysts)
Strong SellHoldStrong Buy
Price Target
$123.00
+14.18% upside
Overview
| ABBV | ABT | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Devices |
| Exchange | NYSE | NYSE |
| Market Cap | $434.70B | $186.53B |
| Shares Outstanding | 1.77B | 1.73B |
| Avg Volume (10D) | 6.08M | 8.95M |
| Dividend Yield | 2.78% | 2.30% |
Frequently Asked Questions
Is ABBV or ABT a better buy right now?
Based on 23 comparable metrics, ABT leads in 12 categories while ABBV leads in 11. ABT has a consensus analyst rating with 27 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, ABBV or ABT?
Over the past year, ABBV returned +24.25% compared to ABT's -17.24%. In the short term (1 month), ABBV returned -0.40% vs ABT's +15.36%.
Is ABBV or ABT more expensive?
ABBV trades at a P/E of 121.16 compared to ABT's 30.18. On a price-to-sales basis, ABBV trades at 6.92x vs ABT's 4.13x. Forward P/E: ABBV at 17.51 vs ABT at 19.55.
Which stock has higher growth, ABBV or ABT?
ABBV's revenue grew +12.43% year-over-year compared to ABT's +7.78%. EPS growth: ABBV at -45.83% vs ABT at -18.24%.
Do ABBV and ABT pay dividends?
ABBV pays a dividend with a yield of 2.78%. ABT pays a dividend with a yield of 2.30%.
Which stock do analysts prefer, ABBV or ABT?
ABBV has 25 analysts with a target price of $283.92 (+15.62% upside). ABT has 27 analysts with a target of $123.00 (+14.18% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.